Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs HSBC Holdings plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while HSBC Holdings plc trades at $103.85 (market cap $353.82B). The key difference: HSBC Holdings plc is far larger — about 12× Alnylam Pharmaceuticals, Inc.'s market cap, and HSBC Holdings plc pays a 3.63% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HSBC | |
|---|---|---|
Market Cap | $29.60B | $353.82B |
Sector | Health | Technology |
52-Week High | $491.22 | $107.86 |
52-Week Low | $205.48 | $63.84 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
